| Malignant neoplasm of breast
Arimidex vs Aromasin
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Arimidex vs Aromasin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAromasin has a higher rate of injection site reactions vs Arimidex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aromasin but not Arimidex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Arimidex
Aromasin
At A Glance
Oral
Daily
Aromatase inhibitor
Oral
Daily
Aromatase inactivator
Indications
- Malignant neoplasm of breast
- Locally advanced breast cancer
- Carcinoma breast stage IV
- Malignant neoplasm of breast
- Advanced breast cancer
Dosing
Malignant neoplasm of breast 1 mg tablet orally once daily; adjuvant treatment duration in the ATAC trial was 5 years.
Locally advanced breast cancer, Carcinoma breast stage IV 1 mg tablet orally once daily; continue until tumor progression.
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Contraindications
- Hypersensitivity to anastrozole or any excipient (including anaphylaxis, angioedema, and urticaria)
- Known hypersensitivity to exemestane or any excipient
Adverse Reactions
Most common (>=10%) Hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, lymphedema
Serious Skin lesions, ulcers, or blisters; severe allergic reactions with swelling of face, lips, tongue, and/or throat; liver function abnormalities including hepatitis
Postmarketing Hepatobiliary events (increases in alkaline phosphatase, ALT, AST, gamma-GT, and bilirubin; hepatitis), erythema multiforme, Stevens-Johnson syndrome, angioedema, urticaria, anaphylaxis, myalgia, hypercalcemia, tendon disorders including tendon rupture and tendonitis
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Pharmacology
Anastrozole is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme, significantly lowering serum estradiol concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone formation.
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Arimidex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Arimidex
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Arimidex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ArimidexView full Arimidex profile
AromasinView full Aromasin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.